azd2423

AZD2423 is a potent, selective, orally bioavailable small molecule that acts as a non-competitive negative allosteric modulator (antagonist) of the chemokine receptor type 2 (CCR2). By binding to CCR2, AZD2423 inhibits its interaction with ligands such as monocyte chemoattractant protein 1 (CCL2), thereby preventing the migration and infiltration of monocytes and reducing inflammation. It was initially developed by AstraZeneca for potential use in conditions involving inflammation and pain, including chronic obstructive pulmonary disease (COPD) and neuropathic pain. Clinical studies have shown that while AZD2423 interacts with its target in vivo, it did not demonstrate significant efficacy in reducing average pain scores compared to placebo in posttraumatic neuralgia trials. The drug has also been investigated for imaging applications using radiolabeled forms for positron emission tomography (PET)[1][5][7][8].